The Business Research Company’s report on the Idiopathic Pulmonary Fibrosis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the idiopathic pulmonary fibrosis industry?
The rise in the prevalence of fibrotic disease is expected to drive the growth of the idiopathic pulmonary fibrosis market going forward. Fibrotic diseases, also known as fibrosis, refer to a group of medical conditions characterized by the excessive formation and accumulation of fibrous connective tissue in various organs or tissues in the body. Idiopathic pulmonary fibrosis drugs help reduce lung fibrosis and inflammation by targeting multiple signaling pathways involved in fibrosis. For instance, in December 2022, according to the American Lung Association, a US-based lung association, there were around 207,000 people affected in the United States and approximately 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year, which is more common in men than women and mainly affects people over 50 years of age. Therefore, the rise in the prevalence of fibrotic disease drives the idiopathic pulmonary fibrosis market.
Access Your Free Sample of the Global Idiopathic Pulmonary Fibrosis Market Report – Get Insights Now!
Idiopathic Pulmonary Fibrosis Market Report 2025, Size, Growth Sample
What is the estimated market size of the idiopathic pulmonary fibrosis sector by 2029, based on current forecasts?
The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development
The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
Idiopathic Pulmonary Fibrosis Market Report 2025, Size, Growth Customise
Who are the top players in the idiopathic pulmonary fibrosis market?
Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
What are the major trends in the idiopathic pulmonary fibrosis market?
Product innovation is a key trend gaining popularity in the idiopathic pulmonary fibrosis market. Major companies operating in the idiopathic pulmonary fibrosis market focus on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2022, Sandoz, a Switzerland-based company that manufactures generic and biosimilar medicines, launched a generic version of pirfenidone, which is the first AB-rated equivalent to Genentech’s Esbriet, aimed at treating individuals suffering from idiopathic pulmonary fibrosis (IPF). This orally administered prescription medication is now accessible to patients through specialty pharmacies, and eligible patients can benefit from a USD 0 co-pay program.
Which geography holds the highest idiopathic pulmonary fibrosis market share?
North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
How do different segments contribute to the overall expansion of the idiopathic pulmonary fibrosis market?
The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users
Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
Idiopathic Pulmonary Fibrosis Market Report 2025, Size, Growth
How is the idiopathic pulmonary fibrosis market defined?
Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue encompassing the air sacs, known as alveoli, in the lungs. This condition leads to the accumulation of scar tissue (fibrosis) within the lungs, impeding the efficient transportation of oxygen into the bloodstream.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
